UCI-led study finds that cancer immunotherapy may self-limit its efficacy
University of California, IrvineIrvine, Calif., June 21, 2021 — Cancer immunotherapy involving drugs that inhibit CTLA-4 also activates an unwanted response that may self-limit its efficacy in fighting tumors, according to a new study led by Francesco Marangoni, Ph.D., assistant professor of physiology & biophysics and member of the Institute for Immunology at the University of California, Irvine.